 The purpose of this study is to determine the efficacy of panitumumab plus cisplatingemcitabine CisGem combination chemotherapy in KRAS wild-type biliary tract cancer patients without systemic pre-treatment, compared to the historical data and to the randomised control group without the antibody, which verifies the historically based assumption. 